We’ve become part of the European Bioprinting Cluster, bringing together Horizon Europe projects working at the bioprinting and regenerative medicine technologies. The cluster goal is to create a collaborative space for European projects address complementary scientific, technological and clinical challenges and help strengthen connections across the bioprinting landscape.
Bioprinting is a rapidly evolving field that relies on expertise from biology, engineering, materials science and clinical research. Through the cluster, participating projects can exchange knowledge, identify shared challenges and explore opportunities for collaboration.
The initiative is organised around three Working Groups focused on key areas of bioprinting innovation:
- Commercialisation: addressing pathways towards clinical adoption, scalability and market implementation
- Compliance with standards and regulations: discussing regulatory frameworks, validation approaches and standardisation challenges
- Communication and dissemination: developing joint outreach activities and increasing the visibility of European bioprinting research.
The European Bioprinting Cluster brings together projects working on a wide range of regenerative medicine applications:
- KeratOPrinter: developing bioprinted human corneas to tackle corneal blindness and donor tissue scarcity
- LUMINATE: creating regenerative therapies for cartilage and bone repair in the knee
- micro2MACRO (m2M): developing scalable bioprinted grafts using microtissue-based approaches
- NEOLIVER: engineering personalised bioprinted liver constructs to address donor organ shortages
- STRONG-UR: developing bioprinting solutions for urethral tissue regeneration
- TENTACLE: advancing minimally invasive 4D bioprinting approaches for colorectal tissue regeneration
By working together, the cluster aims to reinforce collaboration among European initiatives, elevate the profile of research outcomes, and accelerate progress toward clinical translation and regulatory compliance.
For m2M, we believe our participation supports our mission to develop a new bioprinting platform capable of spatially patterning cellular aggregates or microtissues into scaled-up, personalised durable load-bearing grafts and guiding their (re)modelling into fully functional tissues in vivo within damaged or diseased environments, while collaborating on broader bioprinting technologies for future healthcare applications.